drugset
drugset / Trial / NCT03380780

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

NCT03380780 ↗

Phase 1 Completed 16 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This single-center, open-label study will evaluate the pharmacokinetics, safety, and tolerability of emicizumab following a single subcutaneous (SC) administration to healthy Chinese subjects.

Timeline

Start
2018-03-12
Primary completion
2018-09-18
Completion
2018-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Emicizumab Monoclonal antibody 1 mg/kg Subcutaneous

Indications

hemophilia A